Markos Kalligeros
Impact in
- Infectious Diseases top 5%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Health Informatics top 10%
Papers in
- Epidemiology 17
- Liver Disease Diagnosis and Treatment 6
- Influenza Virus Research Studies 5
- Hepatitis B Virus Studies 3
- Neuroendocrine Tumor Research Advances 3
-
- COVID-19 Clinical Research Studies 7
- Co-authors
- Eleftherios Mylonakis (41 shared papers)Fadi Shehadeh (40 shared papers)Evangelia K. Mylona (20 shared papers)Gregorio Benitez (9 shared papers)Philip A. Chan (4 shared papers)Curt G. Beckwith (2 shared papers)Stephanos P. Vassilopoulos (11 shared papers)Athanasios Vassilopoulos (10 shared papers)
- Journals
- Open Forum Infectious Diseases (5 papers)Medicine (4 papers)Frontiers in Pharmacology (3 papers)Pathogens (2 papers)Biology (2 papers)
- Partner nations
- United StatesGreeceCanada
In The Last Decade
Markos Kalligeros
48 papers receiving 1.1k citations
Markos Kalligeros's Hit Papers
Peers
Comparison fields: 5 of 118
- Infectious Diseases 331
- Health Informatics 16
- Neurology 129
- Epidemiology 289
- Modeling and Simulation 30
Countries citing papers authored by Markos Kalligeros
This map shows the geographic impact of Markos Kalligeros's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markos Kalligeros with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markos Kalligeros more than expected).
Fields of papers citing papers by Markos Kalligeros
This network shows the impact of papers produced by Markos Kalligeros. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markos Kalligeros. The network helps show where Markos Kalligeros may publish in the future.
Co-authors
The 25 scholars most cited alongside Markos Kalligeros, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 49 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 309 | |
| 2 | Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017–2020 Hit paper breakdown → | 2023 | 121 |
| 3 | 2020 | 94 | |
| 4 | 2020 | 52 | |
| 5 | 2020 | 44 | |
| 6 | 2023 | 44 | |
| 7 | 2020 | 44 | |
| 8 | 2020 | 30 | |
| 9 | 2019 | 24 | |
| 10 | 2024 | 23 | |
| 11 | 2022 | 22 | |
| 12 | 2019 | 19 | |
| 13 | 2020 | 18 | |
| 14 | 2020 | 17 | |
| 15 | 2020 | 17 | |
| 16 | 2021 | 16 | |
| 17 | 2020 | 15 | |
| 18 | 2019 | 13 | |
| 19 | 2023 | 12 | |
| 20 | 2020 | 12 |
About Markos Kalligeros
Markos Kalligeros is a scholar working on Epidemiology, Infectious Diseases, Neurology, Hepatology and Pulmonary and Respiratory Medicine, having authored 49 papers that have together received 1.1k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (7 papers), Liver Disease Diagnosis and Treatment (6 papers), Influenza Virus Research Studies (5 papers), Long-Term Effects of COVID-19 (4 papers), Hepatitis B Virus Studies (3 papers), Neuroendocrine Tumor Research Advances (3 papers), Respiratory Support and Mechanisms (2 papers) and COVID-19 epidemiological studies (2 papers). The work is most often cited by research in Infectious Diseases (331 citations), Health Informatics (16 citations), Neurology (129 citations), Epidemiology (289 citations) and Modeling and Simulation (30 citations). Markos Kalligeros has collaborated with scholars based in United States, Greece and Canada. Frequent co-authors include Eleftherios Mylonakis, Fadi Shehadeh, Evangelia K. Mylona, Gregorio Benitez, Philip A. Chan, Curt G. Beckwith, Stephanos P. Vassilopoulos, Athanasios Vassilopoulos, Eleftheria Atalla and Mazen Noureddin. Their work appears in journals such as Open Forum Infectious Diseases, Medicine, Frontiers in Pharmacology, Pathogens and Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.